From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours

Emilio Bajetta, Giuseppe Procopio, Sara Pusceddu, Filippo Pietrantonio, Massimo Milione, Marco MacCauro, Elena Verzoni, Valentina Guadalupi, Marco Platania

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Original languageEnglish
Pages (from-to)79-87
Number of pages9
JournalOncology Reviews
Volume3
Issue number2
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Neuroendocrine Tumors
Neoplasms
Pets
Carcinoid Tumor
Therapeutics
Somatostatin
Monoclonal Antibodies
Drug Therapy
Growth

Keywords

  • Angiogenesis
  • Chemotherapy
  • Metastasis
  • Neuroendocrine tumours
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

From biology to clinical experience : Evolution in the knowledge of neuroendocrine tumours. / Bajetta, Emilio; Procopio, Giuseppe; Pusceddu, Sara; Pietrantonio, Filippo; Milione, Massimo; MacCauro, Marco; Verzoni, Elena; Guadalupi, Valentina; Platania, Marco.

In: Oncology Reviews, Vol. 3, No. 2, 06.2009, p. 79-87.

Research output: Contribution to journalArticle

@article{55c3eec34b2b4a9cbd83a7b54e087a82,
title = "From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours",
abstract = "Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.",
keywords = "Angiogenesis, Chemotherapy, Metastasis, Neuroendocrine tumours, Target therapy",
author = "Emilio Bajetta and Giuseppe Procopio and Sara Pusceddu and Filippo Pietrantonio and Massimo Milione and Marco MacCauro and Elena Verzoni and Valentina Guadalupi and Marco Platania",
year = "2009",
month = "6",
doi = "10.1007/s12156-009-0011-x",
language = "English",
volume = "3",
pages = "79--87",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "2",

}

TY - JOUR

T1 - From biology to clinical experience

T2 - Evolution in the knowledge of neuroendocrine tumours

AU - Bajetta, Emilio

AU - Procopio, Giuseppe

AU - Pusceddu, Sara

AU - Pietrantonio, Filippo

AU - Milione, Massimo

AU - MacCauro, Marco

AU - Verzoni, Elena

AU - Guadalupi, Valentina

AU - Platania, Marco

PY - 2009/6

Y1 - 2009/6

N2 - Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

AB - Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

KW - Angiogenesis

KW - Chemotherapy

KW - Metastasis

KW - Neuroendocrine tumours

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=67650665487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650665487&partnerID=8YFLogxK

U2 - 10.1007/s12156-009-0011-x

DO - 10.1007/s12156-009-0011-x

M3 - Article

AN - SCOPUS:67650665487

VL - 3

SP - 79

EP - 87

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 2

ER -